摘要
目的评价α-肾上腺能受体(α-AR)拮抗剂联合M-受体阻滞剂治疗Ⅲ型前列腺炎(慢性前列腺炎/慢性盆底疼痛综合征,CP/CPPS)合并膀胱过度活动症(OAB)的临床疗效和安全性。方法 106例CP/CPPS合并OAB患者随机分为α-AR拮抗剂组(n=56)和联合用药组(n=50),α-AR拮抗剂组单用多沙唑嗪缓释片治疗,联合用药组口服多沙唑嗪和托特罗定缓释片治疗。评估美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)总体评分、膀胱过度活动症症状评分(OABSS)和不良反应等。结果治疗后α-AR拮抗剂组NIH-CPSI总体评分有显著改善(P<0.05),联合用药组患者的NIH-CPSI总体评分、储尿期症状评分、OABSS及OABSS问题3评分均有显著改善(P<0.05),且联合用药组患者上述评分的改善均优于α-AR拮抗剂组(P<0.01)。结论α-AR拮抗剂联合M-受体阻滞剂治疗CP/CPPS合并OAB安全有效,值得临床推广。
Objective To evaluate the clinical therapeutic effect and safety of using α‐adrenergic receptor （α‐AR） antagon and muscularinic antagonist in the treatment of chronic prostatitis or chronic pelvic pain syndrome （CP/CPPS） and over‐active bladder （OAB） .Methods 106 cases of CP/CPPS and OAB were ran‐domly divided into the α‐adrenergic receptor （α‐AR） antagon group （n=56） and the combined medication group （n=50） .Theα‐AR antagon group was treated only with doxazosin extended release （ER） tablets , while the combined medication group was treated with doxazosin and tolterodine ER tablets .The total scores got from National Institutes of Health Chronic Prostati‐tis Symptom Index （NIH‐CPSI） ,the over‐active blad‐der symptom score （OABSS ） and the adverse reactions were recorded . Results The NIH‐CPSI total scores were improved in the α‐AR antagon group .The NIH‐CPSI total scores ,the scores of OABSS and the scores of 3rd question of OABSS were found signi？cantly improved after treatment （ P 〈0.05） in the combination group .The scores in the combined medication group were higher than those in the α‐AR antagon group（ P 〈0.01） .Conclusion The combined use of （α‐AR） antagon and muscularinic antagonist can produce good curative effect on CP/CPPS and OAB.
出处
《山东医学高等专科学校学报》
2014年第2期119-122,共4页
Journal of Shandong Medical College
